GGrantIndex
← Search

Molecular Pharmacology

$3,000P30FY2018CANIH

University Of California At Davis, Davis CA

Investigators

Linked publications, trials & patents

Paper 39725713Paper 39620216Paper 39616300Paper 39488208Paper 39453739Paper 39440945Paper 39384967Paper 39383000Paper 39350111Paper 39345479Paper 39345391Paper 39257973Paper 39252929Paper 39217266Paper 39177582Paper 39168154Paper 39108503Paper 39103353Paper 39056190Paper 39046599Paper 39012466Paper 38990223Paper 38979288Paper 38969563Paper 38947002Paper 38885336Paper 38877132Paper 38865710Paper 38843382Paper 38826195Paper 38803393Paper 38798575Paper 38780011Trial NCT07304011Trial NCT07258446Trial NCT07209215Trial NCT07189195Trial NCT07145112Trial NCT06905509Trial NCT06854159Trial NCT06211335Trial NCT06178354Trial NCT06173362Trial NCT06173349Trial NCT06103682Trial NCT06103669Trial NCT06067776Trial NCT05967533Trial NCT05843448Trial NCT05600686Trial NCT05479578Trial NCT05110781Trial NCT05101356Trial NCT05052528Trial NCT04964505Trial NCT04905810Trial NCT04856189Trial NCT04716699Trial NCT04587687Trial NCT04578600Trial NCT04552704Trial NCT04450173Trial NCT04410302Trial NCT04186988Trial NCT04050085Trial NCT04030559Trial NCT03695250Trial NCT03359460Trial NCT03299088Trial NCT03164486Trial NCT03123978Trial NCT02997761Trial NCT02935205Trial NCT02823990Trial NCT02807805Trial NCT02569723Trial NCT02400814Trial NCT02364609Trial NCT02348255Trial NCT02339168Trial NCT02178241Trial NCT02077998Trial NCT01924260Trial NCT01923337Trial NCT01911507Trial NCT01008566Trial NCT00918645Trial NCT00810719Trial NCT00804310Trial NCT00795665Trial NCT00628654Trial NCT00467077Trial NCT00408499Trial NCT00390429Trial NCT00389922Trial NCT00388115Trial NCT00388089Trial NCT00387660Trial NCT00387322Trial NCT00376727

Abstract

PROJECT SUMMARY/ABSTRACT The Molecular Pharmacology Shared Resource (MPSR) provides a mechanism for high-quality collection, processing and analysis of clinical specimens for pharmacokinetic and correlative studies from clinical trial patients. Additionally, this resource conducts preclinical modeling of novel anticancer agents and therapeutic combinations to explore promising avenues for clinical trial design. The resource participates in all levels of our clinical trials program, from preclinical study rationale, protocol development, novel assay development, specimen collection, correlative analysis of patient material, data analysis and publication. The MPSR offers the following categories of services for our investigators: 1) Specimen Collection: The MPSR oversees blood and other surrogate cell collection for patients enrolled on clinical trials conducted at UCDCCC. This service is utilized by clinical investigators executing clinical trials that include a specimen collection component. Virtually all research blood collection conducted at our Cancer Center on clinical trials patients is overseen by the MPSR, regardless of its complexity. The MPSR has substantial specialized specimen collection and processing capabilities, particularly for pharmacokinetic and pharmacodynamic analysis. This HIPAA-compliant resource meets or exceeds all University, local, state and federal regulations necessary for these services. 2) Correlative Studies: The MPSR is particularly vested in the identification and validation of biomarkers and molecular signatures predictive of patient outcome. In addition to CLIA-certified biomarker testing conducted jointly with the UC Davis Molecular Diagnostics Laboratories utilized in Phase II and III studies, we focus on investigational/developmental assays typically performed in conjunction with our early phase clinical trial program. The MPSR conducts analysis and research at our labs on the Sacramento campus or partners with outside labs or commercial entities. In either scenario, the MPSR is responsible for specimen shipping, tracking and anonymization, and is the recipient of the data generated. 3) Preclinical Modeling: The Shared Resource also conducts preclinical modeling and translational research with clinical impact, and works with UCDCCC investigators to establish and test strategies in the laboratory for personalized medicine that are translatable to the clinic. In addition to a variety of cell line- and traditional xenograft-based analyses, the MPSR functions as a link between clinical investigators at UCD and our colleagues at The Jackson Laboratory (JAX) for studies involving patient-derived xenografts (PDXs). The MPSR is by far the biggest user at UCDCCC of the JAX PDX modeling system and has played an integral role in the development of this resource.

View original record on NIH RePORTER →